

Poster presentations (as of 9/19/23)

Poster Session B

Friday, October 13 | 12:30 pm-4:00 pm

Level 2, Exhibit Hall D

B002: *Pharmacodynamics and antitumor mechanism of FHD-286 in a Phase 1 study in subjects with AML or MDS.* Mike Collins, Foghorn Therapeutics, Cambridge, MA United States.

B003: *Real-world (RW) characterization and frequency of TSC1 and/or TSC2 alterations collected from tumor tissue and liquid biopsies from the Tempus genomic database in patients with advanced cancer.* David J. Kwiatkowski, Brigham and Women's Hospital, Boston, MA United States.

B004: *Molecular crosstalk between NF- κ B and NRF2 signaling affects prognosis in HPV-associated head and neck cancer.* Aditi Kothari, UNC, Chapel Hill, NC United States.

B005: *Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board.* Maud Kamal, Institut Curie, Paris, France.

B006: *High RAS-RAF binding as assessed via proximity ligation assay is associated with sensitivity to KRAS^{G12C} inhibitors in NSCLC.* Ryoji Kato, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL United States.

B007: *Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131).* Mohamed A. Gouda, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B008: *Machine-learning enabled quantification of colocalized multiplex IHC signals with spectral overlap.* Waleed Tahir, PathAI, Boston, MA United States.

B009: *A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.* Daniel Boiarsky, Tufts Medical Center, Boston, MA United States.

B010: *Spatially-resolved prediction of gene expression signatures in H&E whole slide images using additive multiple instance learning models.* Chintan Parmar, PathAI, Boston, MA United States.

B011: *GDF-15 is a biomarker of aggressiveness in epithelioid hemangioendothelioma and is down-regulated by sirolimus through ATF4 suppression.* Alessia Beretta, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

B012: *Validation of the OncoSignature assay, an ACR-368-tailored response-predictive quantitative multiplexed immunofluorescent assay for prediction of sensitivity to the CHK1/2 inhibitor ACR-368 in individual patients with cancer.* Michail Shipitsin, Acrivon Therapeutics, Watertown, MA United States.

B013: *Identification of a Notch transcriptomic signature for breast cancer.* Felix Geist, The healthcare business of Merck KGaA, Darmstadt, Germany.

B014: *Characterization of Nectin-4 protein expression in non-small cell lung cancer patients.* Sean Santos, Bicycle Therapeutics, Cambridge, MA United States.

B015: *Tumor fraction as a predictive factor of outcome of patients referred for oncology early phase clinical trials: Analysis of the STING precision medicine study.* Laila Belcaid, University of Copenhagen, Copenhagen, Denmark.

B016: *AI analysis of histological images accurately identifies luminal subtype urothelial carcinomas characterized by high PPARG expression.* Stefan Kirov, Flare Therapeutics, Boston, MA United States.

B017: *Clinical Utility of Next Generation Sequencing in Advanced Colorectal Cancer: The Earlier The Better.* Ho Jung An, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of.

B018: *MTA-cooperative PRMT5 inhibitors selectively modulate RNA splicing in MTAP-deleted cancer cells across histologies.* Matthew R. Tonini, Tango Therapeutics, Boston, MA United States.

B019: *RNA transcriptome profiling in microsamples of blood.* Alex Chenchik, Collecta, Inc., Mountain View, CA United States.

B020: *SF3B1 hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response.* Philip Bland, ICR, London, United Kingdom.

B022: *Effects of RSO-021 on cytokine profiles of malignant pleural effusions from patients enrolled in the MITOPE phase 1/2 clinical trial.* Brian Cunniff, University of Vermont, Burlington, VT United States.

B023: *The next-generation farnesyltransferase inhibitor KO-2806 constrains compensatory signaling reactivation to deepen responses to KRAS^{G12D} inhibition.* Alison Smith, Kura Oncology, Inc., San Diego, CA United States.

B024: *KO-2806, a next-generation farnesyltransferase inhibitor, potentiates the antitumor activity of cabozantinib in clear cell renal cell carcinoma models.* Jovylyn Gatchalian, Kura Oncology, Inc., San Diego, CA United States.

B025: *The next generation farnesyltransferase inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to enhance the antitumor efficacy of KRAS^{G12C} inhibitor adagrasib in KRAS^{G12C} non-small cell lung carcinoma.* Hetika V. Patel, Kura Oncology, San Diego, CA United States.

B026: *Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer.* Tej Tummala, Legorreta Cancer Center at Brown University, Providence, RI United States.

B027: *Synergy between ONC201 and temozolomide on ATF4 integrated stress response in glioblastoma.* Josephine Chen, Brown University, Providence, RI United States.

B028: *Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-2/Bcl-xL inhibitors.* Kirsi L. J. Toivanen, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

B029: *Targeting phosphodiesterase: A potential strategy to treat LKB1-mutant cancers.* Catherine Rono, Michigan Technological University, Houghton, MI United States.

B031: *IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors.* Martin Wermke, TU Dresden, NCT/UCC Early Clinical Trial Unit, Dresden, Germany.

B032: *Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS^{MULTI} (ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001.* Alexander I. Spira, Virginia Cancer Specialists, NEXT Oncology Virginia, Fairfax, VA United States.

B033: *Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study.* Alison M. Schram, Memorial Sloan Kettering Cancer Center, New York, NY United States.

B034: *A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2).* Ecaterina E. Dumbrava, MD Anderson Cancer Center, Houston, TX United States.

B035: *A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.* Benjamin Schlechter, Dana Farber Cancer Institute, Boston, MA United States.

B037: *A pharmacodynamic pilot study of DS8201a in patients with HER2 expressing advanced solid tumors.* Alice Chen, Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD United States.

B038: *Clinical and Biological Activity of ST101, a Peptide Antagonist of C/EBP β , in Recurrent Glioblastoma (rGBM) Patients. Results From the rGBM Cohort of a Multi-Cohort Phase 2 Study.* Fabio Iwamoto, Columbia University, New York, NY United States.

B039: *A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111 / DEP irinotecan) in patients with advanced solid tumours.* Jia Liu, The Kinghorn Cancer Centre, St Vincent's Hospital; Garvan Institute of Medical Research; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.

B040: *NCI 10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors.* Michael Cecchini, Yale University School of Medicine, New Haven, CT United States.

B041: *A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of Module 1 Dose Escalation.* Elizabeth K. Lee, Dana-Farber Cancer Institute, Boston, MA United States.

B042: *Efficacy and Safety Outcomes of ABN401 in NSCLC Patients with MET Exon 14 Skipping: A Clinically Relevant Subgroup Analysis.* Se-Hoon Lee, Samsung Medical Center, Seoul, Korea, Republic of.

B043: *Preliminary results from a phase I/II study evaluating the safety, tolerability, and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies.* Elena Garralda, Hospital Universitari Vall D'Hebron, Barcelona, Spain.

B044: *Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors.* Simon Rodney, The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.

B045: *Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations:*

Preclinical and Phase 1b results. Ezra Rosen, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY United States.

B046: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study. Christophe Le Tourneau, Department of Drug Development and Innovation, Institut Curie, Paris, France.

B047: Phase I trial of $\alpha\beta3$ integrin cytotoxin ProAgio in patients with previously treated advanced pancreatic cancer and other solid tumor malignancies. Nebojsa Skorupan, National Cancer Institute, Center for Cancer Research, Bethesda, MD United States.

B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302). Khurum Khan, University College London Hospital, London, United Kingdom.

B049: Phase II study of NUC-3373, leucovorin, irinotecan (NUFIRI) + bevacizumab vs FOLFIRI + bevacizumab for the second-line treatment of patients with advanced/metastatic colorectal cancer (NuTide:323). Richard H. Wilson, Beatson West of Scotland Cancer Centre/University of Glasgow, Glasgow, United Kingdom.

B051: PARG inhibition leads to the formation of toxic nuclear PARP1 aggregates. Sateja Paradkar, Yale University, New Haven, CT United States.

B052: Small molecule RPA inhibitors abrogate the ATR kinase signaling pathway. Matthew R. Jordan, Indiana University School of Medicine, Indianapolis, IN United States.

B053: Applying a new drug discovery platform for the discovery and development of inhibitors of DDR proteins APE1 and Pol eta. Debanu Das, XPose Therapeutics Inc, San Carlos, CA United States.

B054: TNG348, a selective USP1 inhibitor, shows strong preclinical combination activity with PARP inhibitors and other agents targeting DNA repair. Antoine Simoneau, Tango Therapeutics, Boston, MA United States.

B055: Characterization of highly selective and CNS-penetrant PARP1 inhibitors. Barry E. McGuinness, Duke Street Bio Ltd, London, United Kingdom.

B056: Modulation of the DNA replication stress response and chemo-response by the mono-ADP-ribosyltransferase PARP14. Ashna Dhoonmoon, Penn State College of Medicine, Hershey, PA United States.

B057: Preclinical development of PKMYT1 and ATR inhibitor combinations. Michal Zimmermann, Repare Therapeutics, St. Laurent, QC Canada.

B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer. Mark Albertella, AstraZeneca, Cambridge, United Kingdom.

B059: Identification of Cohesin RAD21 as a Novel Aneuploidy-Associated Marker Driving Prostate Cancer Progression by Mitigating Toxic DNA Damage. Xiaofeng A. Su, Center for Prostate Disease Research, Bethesda, MD United States.

B060: *Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancer.* Haineng Xu, University of Pennsylvania, Philadelphia, PA United States.

B061: *Sensitivity and resistance mechanisms of human cancer cell lines treated with PARP, POL θ , and ATR inhibitor combinations in 2D and 3D spheroid cell viability assays.* Janneke J.T.M. Melis, Oncolines B.V., Oss, Netherlands.

B062: *Loss of MED12 activates the TGF β pathway to promote chemoresistance and replication fork stability in BRCA-deficient cells.* Lindsey M. Pale, Penn State College of Medicine, Hershey, PA United States.

B063: *Proteasome Inhibitors Induce DNA Damage and Mitotic Catastrophe in Acute Lymphoblastic Leukaemia (ALL) via Autophagy-mediated Degradation of WEE1.* Chun-fung Sin, University of Hong Kong, Hong Kong, Hong Kong (Greater China).

B064: *Single - cell RNA sequencing reveals tumorigenic trajectories of mismatch repair deficient cells.* Alexandra Vitor, Merck KGaA, Darmstadt, Germany.

B065: *Enhancing the therapeutic gain of proton radiotherapy in Locally Advanced Rectal Cancer (LARC) through manipulation of WSB1, ATM, and β -Catenin/c-Myc pathway Ubiquitination.* Cameron M. Callaghan, Mayo Clinic, Rochester, MN United States.

B067: *FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways.* Junjie Chen, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B068: *Modulation of the DNA damage response by novel Ku-DNA binding inhibitors enhances cellular effects of DNA-double strand break inducing agents.* Pamela L. Mendoza-Munoz, Indiana University, School of Medicine, Indianapolis, IN United States.

B069: *Targeting vulnerabilities in double strand break repair in cancer with polymerase theta inhibitors.* Katelyn Noronha, Yale University, New Haven, CT United States.

B070: *Antitumor effect of AZD5305, a selective PARP1 inhibitor, in breast and gastric cancer cells.* Sujin Ham, Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of.

B071: *VRTX180 a novel Pan-KRAS inhibitor.* Uday Kumar Surampudi, VRise Therapeutics, Inc., Cambridge, MA United States.

B072: *CURE-PROs: Proof-of-mechanism for the first reversible self-assembling targeted protein degraders.* Elena Valdambri, Weill Cornell Medicine, New York, NY United States.

B073: *Characterization of Selective, Allosteric Inhibitors of Human XRN1.* Gordon J. Lockbaum, Accent Therapeutics, Lexington, MA United States.

B074: *Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor.* Matthew L. Maddess, Merck & Co., Inc., Rahway, NJ United States.

B075: *Identifying functional allosteric binding sites using a systematic and scalable AMPS screening platform for drug discovery.* Anil K. Padyana, Atavistik Bio, Cambridge, MA United States.

B076: *Discovery of BBT-176 as Fourth Generation EGFR Tyrosine Kinase Inhibitor.* Krishna Babu Duggirala, Korea Research Institute of Chemical Technology, Daejeon, Korea, Republic of.

B078: *Unraveling resistance and optimizing treatment through molecular profiling in patients with NSCLC and oncogenic fusions.* Mihaela Aldea, Gustave Roussy, Villejuif, France.

B079: *Molecular determinants of sensitivity to Polatuzumab-Vedotin.* Sean R. Corcoran, National Cancer Institute, Bethesda, MD United States.

B080: *Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer.* Chendi Li, Massachusetts General Hospital/Harvard Medical School, Boston, MA United States.

B081: *Aurora kinase A inhibition overcomes adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer.* Chendi Li, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA United States.

B082: *A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal DNA (ecDNA) amplification-mediated resistance to KRAS^{G12C} inhibitor in colorectal cancer (CRC).* Sudhir Chowdhry, Boundless Bio, Inc., San Diego, CA United States.

B083: *Secondary KRAS mutations lead to acquired resistance to KRAS^{G12D} inhibitor in colorectal cancer.* Simone Lieb, Boehringer Ingelheim RCV, Wien, Austria.

B084: *Sotorasib/SHP2 inhibitors combo, KRAS^{G12C}(ON)I and RAS^{MULT}(ON)I effectively target KRAS^{G12C} tumors developing secondary resistance to Sotorasib via KRAS^{G12C} amplification.* Hitendra S. Solanki, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL United States.

B085: *Beyond endocrine resistance: Estrogen receptor (ESR1) activating mutations mediate chemotherapy resistance through the JNK/c-Jun MDR1 pathway in breast cancer.* Marwa Taya, Tel Aviv University, Tel Aviv, Israel.

B086: *Targeting ATR to overcome Carboplatin resistance in triple-negative breast cancer patient-derived models.* Juliet Guay, Lady Davis Institute - McGill University, Montreal, QC Canada.

B087: *CTNNB1 mutations can mediate resistance to EGFR targeted therapies in Non-Small Cell Lung Cancer.* Anurima Majumder, Moffitt Cancer Center, Tampa, FL United States.

B088: *VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K/AKT/mTOR pathways.* Tracy T. Tang, Vivace Therapeutics, San Mateo, CA United States.

B089: *MUC1-C is a common driver of acquired osimertinb resistance in NSCLC.* Naoki Haratake, Dana-Farber Cancer Institute, Boston, MA United States.

B090: *Partially open conformation of the G323E mutated HIF-2 α PASB domain captured by X-ray crystallography.* Steven Shia, Arcus Biosciences, Hayward, CA United States.

B091: *Overexpression of Muscleblind Like Splicing Regulator 2 (MBNL2) Enhances Cisplatin Resistance in Ovarian Cancer.* Woong Ju, Ewha Womans University, Seoul, Korea, Republic of.

B092: *Intrinsic genomic plasticity of extrachromosomal DNA (ecDNA) enables oncogene amplified tumor cells to develop rapid acquired resistance to targeted therapy.* Kristen Turner, Boundless Bio, Inc., San Diego, CA United States.

B093: *Treating KRAS(G12D) inhibitor resistance using a KRAS- and HSP90 chaperone-targeted hetero-bispecific small molecule agent.* Ines Pulido, University of Illinois Chicago, Chicago, IL United States.

B094: *Pentraxin 3 promotes the therapy resistance to sorafenib via regulating apoptosis in hepatocellular carcinoma.* Ping-Wen Chen, National Cheng Kung University, Tainan City, Taiwan (Greater China).

B095: *Sacituzumab govitecan-based drug combinations overcome platinum/PARP inhibitor resistance in ovarian cancer models.* Neil T. Conlon, Dublin City University, Dublin, Ireland.

B096: *A comparative assessment of selinexor with trabectedin or lurbinectedin in patient-derived xenografts (PDX) of dedifferentiated liposarcoma (DDLPS) highlights the effectiveness of their sequential or concomitant combination.* Sandro Pasquali, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

B098: *Unbiased in vitro and in vivo drug anchor screens identify mechanisms of resistance and sensitization for MTA-cooperative PRMT5 inhibitors in MTAP-deleted cancer models.* Teng Teng, Tango Therapeutics, Boston, MA United States.

B099: *Targeting Non Small Cell Lung Cancer EGFR-Mutant and EGFR-Inhibitor Resistant Cell Lines by Ferroptosis Induction: A Potential Therapeutic Approach.* Taronish Dubash, Sonata Therapeutics, Watertown, MA United States.

B100: *Charting the transcriptomic landscape of primary and metastatic cancers in relation to their origin and target normal tissues.* Neel Sanghvi, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD United States.

B101: *A phenotypic drug screen identifies a targetable metabolic vulnerability in brain metastases.* Agata M. Kieliszek, McMaster University, Hamilton, ON Canada.

B102: *Predicting small cell lung cancer liver metastasis.* George Chrisafis, National Cancer Institute, Bethesda, MD United States.

B103: *Statins decrease mesothelial clearance, an early step in ovarian cancer metastasis.* Brendan M. Reilly, University of New Hampshire, Durham, NH United States.

B104: *U18666A-induced cholesterol accumulation decreases tumor-derived exosomes load and modulates malignant transformation.* Syed Sultan Beevi, KIMS Foundation and Research Centre, Hyderabad, India.

B105: *Antineoplastic effects and expression modulations in proliferation/apoptosis related genes by riproxim in breast cancer cells.* Asim Pervaiz, Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan.

B106: *Discovery of Covalent NRAS Inhibitors Targeting the Palmitoylation Site through Imaging-Based High-Throughput Screening.* Zhao Wang, Covant Therapeutics, Boston, MA United States.

B107: *Determining the Mechanism of Action of the Anti-ENTPD2 Antibody, KAZ954.* Samantha Zaharevitz, Novartis Institutes for BioMedical Research, San Diego, CA United States.

B108: *NUDT5 inhibition differentially affects IDH1-Wildtype and Mutant high-grade glioma to induce NAD⁺ independent radiosensitization and anti-proliferative effects.* Thomas J.R. Cox, University of Surrey, Guildford, United Kingdom.

B109: *MTHFD1/2 inhibitor TH9619 targets the DNA damage response and causes cancer-specific folate trapping with an unprecedented therapeutic window.* Thomas Helleday, Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

B110: *β 3-adrenergic receptor as a new molecular target in neuroblastoma treatment.* Rossana Putino, Meyer Children Hospital, Florence, Italy.

B112: *SNAP23-dependent SNARE complex is a novel molecular target in AL Amyloidosis and Multiple Myeloma by blocking free light chain secretion and triggering a terminal unfolded protein response.* Emre Karayol, Brigham and Women's Hospital, Boston, MA United States.

B113: *Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers.* Koichi Ito, Prelude Therapeutics Inc., Wilmington, DE United States.

B114: *A Phase 1/1b study of KAZ954 alone and in combination with spartalizumab (PDR001) and taminadenant (NIR178) in patients with advanced gastrointestinal malignancies.* Devalingam Mahalingam, Northwestern University Feinberg School of Medicine, Chicago, IL United States.

B115: *Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor.* Chandrasekar Iyer, Loxo@Lilly, Indianapolis, IN United States.

B116: *Preclinical characterization of orally bioavailable, highly potent pan-KRAS inhibitors with selectivity over HRAS and NRAS.* Lourdes Prieto Vallejo, Eli Lilly and Company, Alcobendas, Spain.

B117: *VRTX153, Novel Small Molecule Inhibitor of KRASG12D.* Prashant Kashinath Bhavar, VRise Therapeutics, Inc., Cambridge, MA United States.

B119: *First-in-class orally active pharmacological inhibitors of TRPV6 for the treatment of advanced prostate cancer.* Gregory Monteith, The University of Queensland, Brisbane, QLD Australia.

B120: *PRISM high-throughput screening of antibody-drug conjugates uncovers clinically relevant targets.* Jillian N. Eskra, Broad Institute of MIT and Harvard, Cambridge, MA United States.

B121: *CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic.* Agnieszka Bojko-Matuszek, Celon Pharma S.A., Preclinical Development Department, Kazuń Nowy, Poland.

B122: *2 for 1: Targeting tumor-associated macrophages and cancer cells with a novel MERTK-targeting antibody-drug conjugate (ADC).* Shugaku Takeda, Inspirna, Inc., New York, NY United States.

B123: *Mechanism of action of ivonescimab (AK112/SMT112): A first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects.* Betty Y. Chang, Summit Therapeutics, Inc., Menlo Park, CA United States.

B124: *MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression.* William C. Comb, Mythic Therapeutics, Waltham, MA United States.

B125: *Neutralizing acidosis with L-DOS47 urease immunoconjugate enhances responses to anti-PD1 checkpoint blockade in a preclinical orthotopic model of pancreatic adenocarcinoma.* Gabrielle M. Siegers, Helix BioPharma Corp, Toronto, ON Canada.

B126: *Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.* Timothy P. DiPeri, MD Anderson Cancer Center, Houston, TX United States.

B127: *Novel Anti-CD147 Antibody DS-1471a Exerts Antitumor Effect in Hepatocellular Carcinoma Patient Derived Xenograft Models and its Efficacy Correlates with the Expression of CD147.* Hiroshi Yuita, Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

B128: *Preclinical characterization of ETx-22, a next-generation antibody drug conjugate (ADC) targeting nectin-4.* Hatem Azim, Emergence Therapeutics AG, Duisburg, Germany.

B129: *A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models.* Yan Yang, Regeneron Pharmaceuticals, Tarrytown, NY United States.

B130: *Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor2 (HER2)-positive Solid Cancers.* Do-Youn Oh, Seoul National University Hospital, Seoul, Korea, Republic of.

B131: *NXC03, an AI-designed, affinity-attenuated IL-21 mutein with half-life extension enhances antitumor immunity.* Taylor B. Guo, neoX Biotech, Shanghai, China (Mainland).

B132: *Addition of AMXT1501 (polyamine uptake inhibitor) plus DFMO (polyamine synthesis inhibitor) to standard-of-care chemotherapy/anti-GD2 antibody in the TH-MYCN mouse neuroblastoma model, enhances efficacy compared to addition of DFMO alone.* Michelle Haber, Children's Cancer Institute, Sydney, Australia.

B133: *Anti-tumor efficacy of GMF-1A3-MMAE, an antibody drug conjugate targeting cell surface cleaved Amphiregulin in endocrine-resistant breast cancer.* Paraic A. Kenny, Gundersen Medical Foundation, La Crosse, WI United States.

B134: *Targeting Philadelphia chromosome-like acute lymphoblastic leukemia with a novel CRLF2 antibody fragment-drug conjugate.* Richard B. Lock, Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, UNSW Medicine & Health, Centre for Childhood Cancer Research, UNSW Sydney, Sydney, NSW, Australia.

B135: *Discovery of VVD-065, a first-in-class allosteric molecular glue of the Keap1-Cul3 E3-ligase complex for the treatment of NRF2-activated cancers.* Matt Patricelli, Vividion Therapeutics, San Diego, CA United States.

B136: *Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability.* Marta Cortes-Cros, Novartis Institutes for BioMedical Research, Basel, Switzerland.

B137: *Selective inhibition of the active state of KRAS^{G12V} with the non-covalent, tri-complex inhibitor RM-048.* Bianca J. Lee, Revolution Medicines, Redwood City, CA United States.

B138: *Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response.* Brian Ko, National Cancer Institute, Bethesda, MD United States.

B139: *Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitor.* Adam Yaari, Serinus Biosciences Inc, New York, NY United States.

B140: *Elucidating the novel mechanism of action of VVD-065, an allosteric molecular glue for the KEAP1-CUL3 E3-ligase complex that promotes NRF2 degradation in NRF2-activated cancers.* Aaron Snead, Vividion Therapeutics, San Diego, CA United States.

B141: *Evaluation of antigen-agnostic anti-tumor activity and immunological memory induced by CBX-15 (alphalexTM-MMAE) in the rat syngeneic breast cancer model.* Vishwas Paralkar, Cybrexa Therapeutics, New Haven, CT United States.

B142: *Discovery of novel and potent TEAD inhibitors, orally available small molecules with anti-tumor activity in hippo pathway- dysregulated cancers.* Seon Yeon Cho, Baobab AiBIO Co., Ltd., Incheon, Korea, Republic of.

B143: *HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSI^{high} models.* Stephane Ferretti, Novartis Institutes for Biomedical Research Oncology Research, Basel, Switzerland.

B144: *Discovery and preclinical evaluation of novel oral WEE1 degraders.* Yang Xie, neoX Biotech, Boston, MA United States.

B145: *Clinical features of progression and outcomes with subsequent therapies in patients treated with RET-inhibitors.* Arianna Marinello, Gustave Roussy, Villejuif, France.

B146: *Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecific antibody conjugated with MMAE in targeted anticancer therapy.* Delfina Popiel, Celon Pharma S.A., Preclinical Development Department, Kazuń Nowy, Poland.

B147: *Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models.* Robert W. Lentz, University of Colorado School of Medicine, Aurora, CO United States.

B148: *Novel Low-Atomic Cluster Ag5 Induced Oxidative Stress And Antiproliferation In Esophageal Squamous Cell Carcinoma Cells.* Akihiro Ohashi, National Cancer Center, Kashiwa, Japan.

B149: *Anti-tumor and immunostimulatory properties of ST316, a peptide antagonist of beta-catenin for treatment of cancers with aberrant Wnt pathway activity.* Lila Ghamsari, Sapience Therapeutics, Tarrytown, NY United States.

B150: *Targeting EWS-FLI1 with mithramycin analogues for Ewing sarcoma treatment.* Markos Leggas, St. Jude Children's Research Hospital, Memphis, TN United States.

B151: *Discovery and characterization of a novel small molecule brain penetrant PD-L1 inhibitor.* Haiyan Ying, Abbisko Therapeutics, Shanghai, China (Mainland).

B152: *Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis.* Xiuning Le, Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B153: *Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations.* Xiuning Le, MD Anderson Cancer Center, Houston, TX United States.

B154: *Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors.* Jessica J. Lin, Massachusetts General Hospital (MGH), Boston, MA United States.

B155: *IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumors.* Eric Haines, Ikena Oncology, Boston, MA United States.

B156: *MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1.* Timothy A. Yap, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX United States.

B157: *Preclinical evaluation of the blood-brain barrier permeability and intracranial efficacy of the next-generation RET inhibitor Vepafestininib.* Igor Odintsov, Brigham and Women's Hospital, Harvard Medical School, Boston, MA United States.

B159: *A First-In-Human Study of CDK9 Inhibitor KB-0742 Demonstrates Evidence of Tolerability and Clinical Activity.* Miguel Villalona-Calero, City of Hope, Duarte, CA United States.

B160: *A phase 1 open-label, dose-escalation study of central nervous system-penetrant cyclin-dependent kinase (CDK)4/6 inhibitor PRT3645 in patients with select advanced or metastatic solid tumors.* Neelesh Sharma, Prelude Therapeutics Incorporated, Wilmington, DE United States.

B162: *NXP900, a novel YES1/SRC kinase inhibitor demonstrates inhibition of YAP1 nuclear localization and potent single agent anti-tumor activity in esophageal squamous cancer models.* Neil O. Carragher, University of Edinburgh, Edinburgh, United Kingdom.

B163: *Discovery and characterization of OKI-219, an orally bioavailable H1047R-mutant-selective inhibitor of PI3K α .* Molly A. Taylor, OnKure Inc, Boulder, CO United States.

B164: *ASTX029 is a dual mechanism ERK1/2 inhibitor with activity in models of MAPK-inhibitor resistance.* Joanne Munck, Astex Pharmaceuticals, Cambridge, United Kingdom.

B165: *A pharmacologic screen identifies drugs to be combined with the non-ATP competitive PI3K δ inhibitor roginolisib (IOA-244) for an improved anti-tumor activity in lymphoma models.* Francesco Bertoni, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

B167: *Preclinical characterization of THE-349, a mutant-selective, CNS-active, fourth-generation EGFR inhibitor to overcome T790M- and C797S-mediated resistance in NSCLC.* Sen Zhang, Theseus Pharmaceuticals, Inc, Cambridge, MA United States.

B168: *Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations.* Raymond A. Pagliarini, Scorpion Therapeutics, Boston, MA United States.

B169: *Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring CCNE1 amplification and/or deleterious alterations in FBXW7 or PPP2.* Elia Aguado-Fraile, Repare Therapeutics, Cambridge, MA United States.

B170: *The in vitro anti-tumor activity of the multi-kinase inhibitor nemtabrutinib (ARQ-531, MK-1026) is seen across multiple B-cell lymphoma subtypes, only partially overlapping with what achieved by single BTK inhibition.* Giulio Sartori, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

B171: *BX-795 enhances the efficacy of crizotinib in colorectal cancer cells by altering the activity of aurora kinases.* Rajat Bhattacharya, The University of Texas M.D. Anderson Cancer Center, Houston, TX United States.

B172: *Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor.* Susanta Samajdar, Aurigene Oncology Limited, Bangalore, India.

B173: *The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers.* Yaoyu Chen, Allorion Therapeutics, Natick, MA United States.

B174: *The non-covalent HCK/BTK inhibitor TTX-114 displays potent in vitro and in vivo anti-tumor activity in leukemia and lymphoma.* Ulrike Rauh, Trueline Therapeutics Inc, Berlin, Germany.

B175: *In-vitro Multicellular 3D-Spheroid Model Demonstrates the Synergistic Effect of 2-Domain Soluble FMS-Like Tyrosine Kinase-1 (2d-sFlt-1) for Breast Cancer Targeted Therapies.* Adel Zaid I. Mutahar, Molecular Oncology Lab., Department of Studies in Biotechnology, University of Mysore, Mysore, India.

B177: *The discovery and preclinical characterization of AMG 193, a first-in-class MTA-cooperative PRMT5 inhibitor with broad activity against MTAP-null cancers.* Paul E. Hughes, Amgen, Thousand Oaks, CA United States.

B178: *Proteomics platform identifies vulnerabilities for specific DNA damage repair drugs.* Gali Arad, Protai Bio, Tel Aviv, Israel.

B179: *2-Deoxy-D-glucose (2-DG) combination with ketogenic diet induces sedation and hypothermia in mice that becomes lethal.* Rafal Zielinski, UT. MD Anderson Cancer Center, Houston, TX United States.